Dl-Phenylalanine

Dl-Phenylalanine

SCHEMBL3117407

NC(Cc1ccccc1)C(=O)O.[Cr]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.96
PTGS1 P23219 2/20 0.96
ALPI P09923 1/20 0.96
PKM P14618 1/20 0.96
XIAP P98170 1/20 0.96
SLC1A3 P43003 2/20 0.67
SLC1A2 P43004 2/20 0.67
SLC1A1 P43005 2/20 0.67
SLC15A1 P46059 1/20 0.61
CYP1A2 P05177 1/20 0.59
LTA4H P09960 1/20 0.58
GRIA2 P42262 1/20 0.57
KDM4E B2RXH2 1/20 0.56
USP2 O75604 1/20 0.56
EGFR P00533 1/20 0.56
LCK P06239 1/20 0.56
FYN P06241 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
ALOX15 P16050 1/20 0.56
HTR2A P28223 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylalanine SCHEMBL3117414 1.00 SLC7A5 (0.96) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL991787 1.00 SLC7A5 (0.96) SLC7A5PTGS1ALPIPKMXIAP
D-Phenylalanine SCHEMBL5288072 1.00 SLC7A5 (0.96) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL991789 1.00 SLC7A5 (0.96) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL23159186 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL8119 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL16398196 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL8118 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL385804 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL16398197 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4069206-B1 SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF ALESCO SRL (IT) 2024-08-07 EP claimed
US-20230013586-A1 SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF PHARMANUTRA S.P.A. (IT) 2023-01-19 US claimed
EP-4069206-A1 SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF Alesco S.r.l. (IT) 2022-10-12 EP claimed
US-20210330752-A1 FEED SUPPLEMENTS OMNIGEN RESEARCH, LLC (US) 2021-10-28 US claimed
CN-113556943-A Feed supplement 奥姆尼根研究有限责任公司 2021-10-26 CN claimed
WO-2021111407-A1 SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF ALESCO S.R.L. (IT) 2021-06-10 WO claimed
CN-112675160-A Amino acid mineral salt trace element composition and preparation method thereof 河北力维素科技有限公司 2021-04-20 CN claimed
WO-2020142305-A1 FEED SUPPLEMENTS OMNIGEN RESEARCH, LLC (US) 2020-07-09 WO claimed
US-20170202244-A1 COMPOSITIONS AND COMBINATIONS FOR USE AS FOOD SUPPLEMENTS FOR ANIMALS OMNIGEN RESEARCH, LLC (US) 2017-07-20 US claimed
US-20100178362-A1 CHROMIUM COMPLEXES FOR IMPROVEMENT OF MEMORY AND COGNITIVE FUNCTION CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT 2010-07-15 US claimed
WO-2009009393-A2 CHROMIUM COMPLEXES FOR IMPROVEMENT OF MEMORY AND COGNITIVE FUNCTION NUTRITION 21, INC. (US) 2009-01-15 WO claimed
US-20260097054-A1 ARGININE SILICATE INOSITOL FOR IMPROVING COGNITIVE FUNCTION NUTRITION21 LLC (US) 2026-04-09 US disclosed
US-20250275982-A1 SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF ALESCO S.R.L. (IT) 2025-09-04 US disclosed
US-20240269197-A1 INSULIN-SENSITIZING AGENT AND BUTYRATE-PRODUCING BACTERIUM Caelus Lifesciences IP B.V. (NL) 2024-08-15 US disclosed
EP-4069206-B1 SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF ALESCO SRL (IT) 2024-08-07 EP disclosed
CN-102898338-A Alpha-amino acid chromium (III) chelate and preparation method thereof INST PROCESS ENG CAS 2013-01-30 CN disclosed
EP-2485747-A1 DNA-DIRECTED CUSTOMIZATION OF ANALGESIC COMPOUNDS AS A THERAPEUTIC MODALITY Kenneth Blum, Inc. (US) 2012-08-15 EP disclosed
US-20100178362-A1 CHROMIUM COMPLEXES FOR IMPROVEMENT OF MEMORY AND COGNITIVE FUNCTION CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT 2010-07-15 US disclosed
WO-2009155585-A1 N UTRAGENOMICS KENNETH BLUMY (US) 2009-12-23 WO disclosed
WO-2009009393-A2 CHROMIUM COMPLEXES FOR IMPROVEMENT OF MEMORY AND COGNITIVE FUNCTION NUTRITION 21, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269197-A1 INSULIN-SENSITIZING AGENT AND BUTYRATE-PRODUCING BACTERIUM CPT1A, GPR119, IRS1 SLC7A5 3711/4885PTGS1 1358/4885ALPI 499/4885
US-20260097054-A1 ARGININE SILICATE INOSITOL FOR IMPROVING COGNITIVE FUNCTION NOS2, NOS1, SMS SLC7A5 298/4885PTGS1 1444/4885ALPI 353/4885
US-20210330752-A1 FEED SUPPLEMENTS IGFBP6, CHI3L2, IGFBP3 SLC7A5 2691/4885PTGS1 3720/4885ALPI 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.